NorthWest Biotherapeutics Inc (NWBO)

[Basin Street Blues]

Thats good - I have also made a call to someone very close to the situation.
and they have promised to find out for me .

In an earlier post Flipper concluded with :

"My hope is that LP meant if there was any question once the CRO looked at the data after the halt recommendation, then their preference would be to go to the next IA, and if after a second halt recommendation, the CRO still did not see clear enough data, they would wait to finish the trial. However, I hope she did not mean, "if we get unequivocal results at the first or second interim for significant efficacy" we are still intent on waiting until the end of the trial. If they see what they are looking for by the first or certainly the 2nd interim, to me it would be illogical to keep the trial blinded. Hopefully there is more trust with the FDA than that on the safest therapy that exists in the oncology world -- especially where they are working closely with the FDA on this orphan indication "

I think we all agree with him .